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Malaria is a systemic disease caused by infection 
with parasitic protozoa of the genus Plasmodium 
(1). Death results principally from the compli-
cations of infection: cerebral disease leading to 
intractable coma and a severe and refractory an-
emia producing hypoxemia and cardiac decom-
pensation. These complications of Plasmodium 
infection have been estimated to account for 
at least 1–2 million deaths yearly, mostly in 
  African children under the age of fi  ve (1, 2).
The anemia of malaria infection is the result 
of pathologic processes that act both to acceler-
ate red cell destruction and to inhibit new red 
cell production (3–5). Once infected by malar-
ial parasites, red cells undergo lysis as a result 
of the process of schizogony, wherein the cell 
ruptures to release newly formed merozoites. 
Immune-mediated lysis, phagocytosis, and se-
questration also occur, and these contribute to 
the increased clearance of nonparasitized as 
well as parasitized cells (6, 7). Importantly, recent 
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The pathogenesis of malarial anemia is multifactorial, and the mechanisms responsible for 
its high mortality are poorly understood. Studies indicate that host mediators produced 
during malaria infection may suppress erythroid progenitor development (Miller, K.L., 
J.C. Schooley, K.L. Smith, B. Kullgren, L.J. Mahlmann, and P.H. Silverman. 1989. Exp. Hematol. 
17:379–385; Yap, G.S., and M.M. Stevenson. 1991. Ann. NY Acad. Sci. 628:279–281). We 
describe an intrinsic role for macrophage migration inhibitory factor (MIF) in the develop-
ment of the anemic complications and bone marrow suppression that are associated with 
malaria infection. At concentrations found in the circulation of malaria-infected patients, 
MIF suppressed erythropoietin-dependent erythroid colony formation. MIF synergized with 
tumor necrosis factor and 𝗄 interferon, which are known antagonists of hematopoiesis, 
even when these cytokines were present in subinhibitory concentrations. MIF inhibited 
erythroid differentiation and hemoglobin production, and it antagonized the pattern of 
mitogen-activated protein kinase phosphorylation that normally occurs during erythroid 
progenitor differentiation. Infection of MIF knockout mice with Plasmodium chabaudi 
resulted in less severe anemia, improved erythroid progenitor development, and increased 
survival compared with wild-type controls. We also found that human mononuclear cells 
carrying highly expressed MIF alleles produced more MIF when stimulated with the malarial 
product hemozoin compared with cells carrying low expression MIF alleles. These data 
suggest that polymorphisms at the MIF locus may infl  uence the levels of MIF produced in 
the innate response to malaria infection and the likelihood of anemic complications.
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studies have led to the conclusion that enhanced red cell 
clearance alone does not adequately explain the development 
of malarial anemia, especially in those patients who develop 
a severe, life-threatening disease (8, 9). Severe anemia can 
occur in patients despite low parasitemia or as a result of 
chronic subclinical infection, and it can persist for weeks after 
the patient has been cured of infection and relocated to a 
nonmalarial region (8, 10).
Detailed hematological studies in patients with severe 
malarial anemia emphasize that bone marrow abnormalities 
such as ineff  ective erythropoiesis, dyserythropoiesis, and 
lower erythroblast proliferative rates contribute importantly 
to the development of severe refractory anemia (9, 11–13). 
Malaria-infected patients frequently show a suboptimal 
  reticulocyte count for the degree of anemia even in the face 
of an appropriately high level of circulating erythropoietin, 
which is the hormone critical for bone marrow erythro-
poiesis (14–16). These fi  ndings have been supported by 
  experimental studies in mice (17–20). Collectively, these 
observations have served to focus attention on the pathogen-
esis of the bone marrow suppression that occurs during ma-
laria infection and on the mechanisms that may contribute to 
the resistance of erythroid progenitor cells to the action of 
circulating erythropoietin (21).
Several investigators have proposed that a dysregulation 
in host immunologic pathways is responsible for the sup-
pression of erythropoiesis during malaria infection (22, 23). 
  Potential mechanisms include an excessive or a sustained innate
immune response (24) and a polarization of the adaptive 
T cell response toward the production of mediators that 
might suppress normal pathways of erythropoietic develop-
ment (15, 25, 26). Experimental studies in mice support the 
concept that malaria infection induces in the host the pro-
duction of a potent circulating inhibitor of erythropoiesis 
(19, 27, 28). This erythropoiesis inhibitor has been partially 
characterized with respect to its biologic and biophysical 
properties (27, 28). Cytokines such as TNFα, IL-1β, and 
IFNγ that are produced systemically during malaria infection 
have been considered as candidates for this inhibitory media-
tor, but experimental studies have ruled out an important 
role for these cytokines in mediating erythroid suppression 
(20). A recent and unexpected set of observations from ma-
laria vaccine trials also has focused attention on the immuno-
pathogenesis of malarial anemia (29). Vaccination and challenge 
infection in Aotus monkeys produces severe anemia in a 
  subset of animals that achieves initial immunity. The precise 
explanation for this vaccine-related anemia is unknown, but 
hematologic investigations in these hosts have supported 
a role for impaired erythropoiesis.
In this study, we have investigated whether the immuno-
regulatory cytokine macrophage migration inhibitory factor 
(MIF) plays a role in the pathogenesis of malaria anemia. MIF 
has been proposed to contribute to the pathogenesis of malaria 
based on its abundant expression in an experimental mouse 
model and on the biophysical features it shares with the previ-
ously characterized circulating inhibitor of erythropoiesis (30). 
Using a combination of in vitro studies of erythroid progeni-
tors and in vivo studies in MIF-KO mice, we show that MIF 
has an intrinsic role in the pathogenesis of the bone marrow 
suppression that occurs during malaria infection.
RESULTS
Effect of MIF and proinfl  ammatory cytokines 
on erythropoiesis in vitro
Several infl  ammatory cytokines interfere with hematopo-
iesis, and there is evidence that MIF may inhibit progenitor 
development in vitro (30). We examined the eff  ect of MIF 
on mouse erythroid precursor development using defi  ned 
erythropoietin-dependent colony assays, including both the 
early burst-forming unit erythroid (BFU-E) and the late 
CFU   erythroid (CFU-E). We also studied the two infl  am-
matory   cytokines TNFα and IFNγ, which are produced as a 
consequence of macrophage and T cell activation and are 
implicated in severe malarial anemia (4). The appearance of 
BFU-E and CFU-E were quantifi  ed after culture with these 
Figure 1.  Dose-dependent impact of MIF, TNF𝗂, and IFN𝗄 on colony 
formation in mouse bone marrow progenitor cultures in vitro. Bone 
marrow cells were harvested and plated in a methylcellulose-based 
  medium, and colony numbers were scored after the addition of mouse 
cytokines (see Materials and methods). Individual assays were performed 
in duplicate, and the data shown is a compilation of three to six indepen-
dently performed experiments. Percent inhibition of colony formation is 
calculated with reference to a cytokine-minus control. All values shown 
are the mean ± SD (error bars) and are signifi  cant when compared with 
wells with no cytokine addition (P < 0.05). CFU-E, CFU erythroid; BFU-E, 
burst-forming unit erythroid.JEM VOL. 203, May 15, 2006  1187
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cytokines, which were applied either alone or in combina-
tion. As shown in Fig. 1, the addition of 10–100 ng/ml MIF, 
1–20 ng/ml TNFα, or 10–100 U/ml IFNγ dose depend-
ently inhibited BFU-E and CFU-E colony formation. The 
early stage BFU-E showed greater inhibition than the late 
stage CFU-E colonies at each of the doses tested. Notably, 
the addition of subinhibitory concentrations of MIF together 
with TNFα and IFNγ resulted in a profound and synergistic 
inhibitory action. Synergism in eff  ector function is not un-
usual for cytokine action, and the ability of MIF to lower the 
response threshold to other cytokines has been noted in prior 
studies of other cell systems (31–33).
MIF suppresses erythroid differentiation in progenitor 
cell lines
We next sought to identify the potential pathways responsi-
ble for the MIF-mediated impairment of erythroid diff  eren-
tiation. Erythroid progenitors such as the Friend mouse 
erythroleukemia (MEL; reference 34) or the human K562 
(35) cell line undergo cytodiff  erentiation in vitro, leading to 
the initiation of hemoglobin synthesis and to a more mature 
erythroid phenotype. We examined these model cell systems 
because they replicate certain features of erythroid diff  erenti-
ation and they are more amenable to biochemical analysis 
than methylcellulose cultures of primary progenitor cells.
Cultured MEL cells were induced to undergo cytodiff  er-
entiation in the presence of recombinant MIF and were ana-
lyzed for intracellular hemoglobin content by benzidine 
staining. At a test concentration of 200 ng/ml, which is an 
amount of MIF that may circulate during severe systemic in-
fection (36, 37), MIF decreased the cytodiff  erentiation re-
sponse of MEL cells (Fig. 2 A). The specifi  city of this eff  ect 
was verifi  ed by the application of a neutralizing anti-MIF 
mAb. Quantifi  cation of cellular hemoglobin by a sensitive 
chemical analysis also showed that lower amounts of MIF (20 
and 100 ng/ml) reduced hemoglobin content by 12 and 20%, 
respectively (Fig. 2 B).
We then tested the eff  ect of MIF stimulation on the hu-
man K562 progenitor cell line by coculturing these cells 
under diff  erentiation conditions in the presence of MIF. As 
shown in Fig. 3 A, MIF inhibited the terminal erythropoi-
etic diff  erentiation of these cells as measured by a sensitive 
diaminofl  uorene (DAF) stain (38). The impact of MIF on 
hemoglobin production in these cells also was verifi  ed by 
biochemical quantifi  cation of intracellular hemoglobin con-
tent (Fig. 3 B). Neither MIF nor anti-MIF was found to exert 
cytotoxic eff  ects on erythroid progenitors as assessed by try-
pan blue exclusion (unpublished data).
MIF modulates MAP kinase activation
Having uncovered a prominent inhibitory eff  ect of MIF on 
the diff  erentiation of K562 cells, MEL cells, and primary 
erythroid progenitors, we next examined the signaling 
mechanisms infl  uenced by MIF stimulation. Erythropoiesis 
requires the coordinate activation of several growth factor–
dependent signal transduction pathways (39, 40), and some 
of these pathways may be faithfully represented in model 
progenitor cell systems. For example, both primary erythroid 
and K562 progenitor cells exhibit diff  erentiation-dependent 
modulation in the   diff  erent subfamilies of the mitogen-
  activated protein (MAP)   kinases (extracellular signal-related 
kinase [ERK]–1/2, c-Jun NH2-terminal kinase [JNK]–1/2, 
and p38; reference 35).
MIF promotes proinfl  ammatory functions in monocytes/
macrophages and fi  broblasts by activating the ERK-1/2 
  family of MAP kinases (41). A distinguishing feature of MIF 
Figure 2.  MIF inhibits cytodifferentiation and hemoglobin syn-
thesis of MEL cells. (A) Photomicrographic images of benzidine-stained 
cells from three experiments (I, II, and III) cultured with or without differ-
entiation medium for 96 h together with 200 ng/ml recombinant mouse 
MIF or MIF plus 100 μg/ml anti-MIF mAb. (B) Intracellular hemoglobin 
quantifi  cation of lysed MEL cells (4 × 105 cells per experiment) as de-
scribed in Materials and methods. Each value represents the mean ± SD 
(error bars) of fi  ve different experiments. *, P < 0.01 versus control.1188  MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
  action is that it induces a sustained rather than a transient 
  pattern of ERK-1/2 activation (41), which is noteworthy 
  because the kinetics of ERK-1/2 activation infl  uence the 
  diff  erentiation pathway of diff  erent progenitor cell types (42). 
We cultured K562 progenitors in diff  erentiation medium to-
gether with MIF or MIF plus a neutralizing anti-MIF mAb 
and analyzed the cell lysates using phospho-specifi  c antibodies 
directed against diff  erent MAP kinases. In agreement with 
published results (35), we observed that the erythroid diff  eren-
tiation of K562 progenitors is associated with a time-dependent 
inhibition of ERK-1/2 and JNK-1/2 phosphorylation (begin-
ning at 16 and 96 h, respectively) and a complementary acti-
vation of the p38 phosphorylation (beginning at 16 h; Fig. 4, 
A–C). MIF addition markedly aff  ected these diff  erentiation-
associated MAP kinase responses. In the case of the ERK-1/2 
subfamily, phosphorylation was high at 16 h after MIF stimu-
lation and, in a pattern that is consistent with other primary 
cell types (41), was sustained for a period of at least 96 h 
(16 h, P < 0.01; 96 h, P < 0.05; Fig. 4 A). MIF addition also 
appeared to up-regulate JNK-1/2 phosphorylation when 
compared with diff  erentiation medium alone; however, this 
eff  ect was not as pronounced as for ERK-1/2 and did not 
reach statistical signifi  cance (96 h, P < 0.06; Fig. 4 B). Nev-
ertheless, the diff  erentiation-associated changes in p38 MAP 
kinase phosphorylation were reduced by MIF (16 h, P < 
0.01; 96 h, P < 0.04; Fig. 4 C). The phosphorylation pat-
terns induced by MIF were normalized by anti-MIF mAb 
(96 h: ERK-1/2, P < 0.04; p38, P < 0.04; for anti-MIF 
mAb treatment vs. nontreatment), and the time course for 
these eff  ects was consistent with the increase in hemoglobin 
synthesis observed after anti-MIF treatment (Figs. 3 and 4). 
These data support the role of MIF in inhibiting erythroid 
diff  erentiation by modulating MAP kinase activation.
MIF mediates anemia in experimental malaria infection
After intraperitoneal injection with a modest inoculum of 
Plasmodium chabaudi–parasitized red blood cells (106 per 
mouse), the BALB/c mouse strain develops an acute parasit-
emia that peaks on approximately day 8 of infection (43). 
More than 50% of mice will succumb to infection by 3 wk, 
and anemia notably contributes to death because the admin-
istration of a blood transfusion late in infection can rescue up 
to 90% of the infected mice (44).
To determine the role of MIF in the anemic complica-
tions of acute malaria infection in vivo, we backcrossed a 
  recently developed MIF-KO strain (45) into the BALB/c 
genetic background for experimental infection with P. chabaudi. 
Before study, we fi  rst assessed the hematopoietic competence 
of the MIF-KO strain by bone marrow histochemistry and 
enumeration of the diff  erent hematopoietic lineages. There 
were no diff  erences between wild-type controls and MIF-
KO mice with respect to the number of mature peripheral 
blood cells or in the numbers of CFU-E and BFU-E in bone 
marrow (unpublished data). Infection of wild-type or MIF-
KO mice with P. chabaudi AS resulted in a prominent para-
sitemia that peaked on postinfection day 8 at 47 ± 15%. 
Peripheral blood was sampled every 2 d, and there was no 
appreciable diff  erence in the mean level of parasitemia in the 
wild-type versus the MIF-defi  cient mice over the 4-wk course 
of the study (unpublished data). Despite the similar levels of 
parasitemia, however, the severity of anemia that developed 
in the two diff  erent experimental groups was quite diff  erent, 
especially as the infection progressed (Fig. 5 A). Hemoglobin 
levels progressively declined in the wild-type mice, with the 
lowest levels recorded on postinfection day 15, after which 
time >90% of the animals in this group perished. In compar-
ison, the MIF-KO mice experienced a less severe anemia 
than the wild-type mice, and this diff  erence remained statisti-
cally signifi  cant after the fi  rst week. Notably, the onset of 
death for mice in the MIF-KO group was   delayed by 2 d 
Figure 3.  MIF inhibits cytodifferentiation and hemoglobin produc-
tion in human (K562) erythroid progenitors. (A) Terminal erythropoi-
etic differentiation was assayed as described in Materials and methods 
with diaminofl  uorene (DAF) after culture in differentiation medium to-
gether with 200 ng/ml MIF for 96 h as described in Materials and meth-
ods. The neutralizing anti-MIF mAb was added at 100 μg/ml. DAF-positive 
cells were enumerated and expressed as fold change over total input cells. 
(B) Cellular hemoglobin content of cultured K562 progenitor cells. An 
isotypic control (IgG1) added in the same concentration had no impact on 
MIF’s inhibitory action, nor did anti-MIF infl  uence differentiation in the 
absence of MIF (not depicted). Each value represents the mean ± SD 
  (error bars) of at least three different experiments. *, P < 0.01 versus 
 corresponding  controls.JEM VOL. 203, May 15, 2006  1189
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when compared with wild-type mice (P = 0.013; Fig. 5 B). 
Moreover, although almost 30% of the MIF-KO mice sur-
vived to postinfection day 30, only 9% of wild-type mice 
survived this long (P < 0.04).
To better assess the role of the host infl  ammatory response 
in the development of anemia and lethality from P. chabaudi 
infection, we measured the production of MIF and the cyto-
kines TNFα and IFNγ, which serve as useful indicators of 
systemic macrophage and T cell activation, respectively. 
Plasma MIF concentrations reached 40 ± 20 ng/ml in wild-
type mice at day 8 (Fig. 5 C). However, serum TNFα and 
IFNγ levels showed no diff  erences when measured in the 
MIF-KO and wild-type strain during the period critical for 
anemia and lethality. Collectively, these fi  ndings support an 
important role for MIF, independent of the contribution of 
TNFα or IFNγ, in the development of the malaria infec-
tion–related complications of anemia and death.
To further evaluate MIF’s role in the development of 
anemia and erythroid suppression in this model of malaria in-
fection, we next examined hematopoietic parameters in these 
mice. Malaria infection produced a reticulocytosis in both 
the wild-type and MIF-KO strains, but the corrected reticu-
locyte count was much greater in the setting of MIF defi  -
ciency (MIF+/+, 8 ± 5% vs. MIF−/−, 23 ± 10%; day 10 after 
infection; P < 0.01). We also measured CFU-E and BFU-E in 
bone marrow, and colony formation was signifi  cantly greater in 
the P. chabaudi–infected MIF-KO mice than in the correspond-
ing P. chabaudi–infected wild-type mice (P < 0.01; Fig. 6 A). 
Figure 4.  Western blot analysis of the phosphorylation of MAP 
kinase proteins ERK-1/2, JNK-1/2, and p38 in response to cytodif-
ferentiation and MIF treatment of K562 erythroid progenitors. For 
each experiment, 30 μg of cell lysates were subjected to SDS-gel electro-
phoresis and electroblotting followed by incubation with specifi  c anti-
phospho–ERK-1/2 or total ERK (A), antiphospho–JNK-1/2 or total JNK 
antibodies (B), and antiphospho-p38 or total p38 antibodies (C). 100 μg/ml 
of neutralizing anti-MIF mAb showed no infl  uence on MAP kinase activa-
tion in the absence of exogenously added MIF (not depicted). One repre-
sentative blot is shown from at least three independently performed cell 
culture experiments for each kinase analysis. (D) Densitometric values 
were calculated as the ratio of phosphorylated to total MAP kinase as 
described in Materials and methods (n = 3 blots from independent ex-
periments; mean ± SEM). Signifi  cance was calculated for each treatment 
condition (MIF or MIF + anti-MIF) versus nontreatment for each time 
point (4, 16, and 96 h).1190  MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
Notably, the levels of bone marrow production of the cyto-
kines TNFα and IFNγ were indistinguishable in the infected 
MIF-KO and wild-type strains, and the measured values 
closely mirrored the circulating levels of these mediators 
(Figs. 5 C and 6 B). The wild-type mice nevertheless showed 
a prominent induction of MIF protein in the bone marrow 
that increased over time during the period critical for anemia 
development. These data collectively support the role of MIF 
in erythroid suppression and that MIF defi  ciency is associated 
with better compensation of erythropoiesis during experi-
mental malarial infection.
MIF circulates in high concentrations in malaria patients
Recent investigations in human malaria have provided evi-
dence for MIF production in the intervillous blood of preg-
nant women with placental infection (46, 47). To determine 
whether clinical malaria infection is associated with an in-
crease in MIF in the systemic circulation, we used a specifi  c 
sandwich ELISA to quantify MIF in patients residing in a 
Plasmodium falciparum–endemic region of Zambia. MIF was 
measured in 20 children who were presented sequentially for 
clinical evaluation and diagnosed with malaria by peripheral 
blood smear. As shown in Fig. 7, there was a signifi  cant in-
crease in the plasma concentration of MIF in malaria-infected 
patients when compared with uninfected controls obtained 
from the same geographic region. The median plasma con-
centrations of MIF in the malarial patients was 11.8 ng/ml 
(0.9–49.5 ng/ml), which is comparable with the level re-
ported previously in patients with bacterial sepsis (median of 
12.2 ng/ml; reference 36). These data support the conclusion 
that Plasmodium infection is a potent stimulus for the systemic 
expression of MIF in human subjects.
A functional promoter polymorphism in human 
MIF infl  uences the MIF response to the malarial 
product hemozoin
The evidence that MIF plays a role in malarial anemia 
prompted us to examine whether genetic polymorphisms in 
Figure 5.  Malaria-infected MIF-KO mice (MIF−/−) suffer from less 
severe anemia and show increased survival when compared with 
genetically matched wild-type controls (MIF+/+). (A) Time course for 
the development of anemia as assessed by peripheral blood sampling 
every other day. The data shown are the means ± SD (error bars) of 10 
mice per group from one of two experiments that yielded similar results. 
For differences in mean hemoglobin concentrations between the MIF+/+ 
and MIF−/− mice, P values are as follows: *, P < 0.01 for days 6, 8, and 15; 
*, P < 0.05 for days 10 and 12. Because of low numbers of survivors, the 
wild-type mice were not further studied after day 15. (B) Kaplan-Meyer 
survival curves for MIF+/+ and MIF−/− mice after infection with 
P. chabaudi AS. The data shown are for all mice studied (MIF+/+, n = 30; 
MIF−/−, n = 31). The median survival was 13 d for MIF+/+ mice and 15 d 
for MIF−/− mice. P = 0.0113 (two-tailed Mann-Whitney test); for overall 
survival, P < 0.04 (χ2 test). (C) Plasma MIF, TNFα, and IFNγ concentra-
tions measured by ELISA in P. chabaudi–infected wild-type (MIF+/+) and 
MIF-KO (MIF−/−) mice. Cytokines were measured in triplicate. (The MIF-KO 
mice do not produce any immunoreactive MIF product). For TNFα and 
IFNγ, there were statistically signifi  cant increases on postinfection days 8 
and 12 compared with uninfected controls in both strains (*, P < 0.001).JEM VOL. 203, May 15, 2006  1191
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the human MIF gene infl  uence the human host response to 
malaria infection. Functional promoter polymorphisms in hu-
man MIF have been linked recently both to the incidence or 
the severity of several infl  ammatory diseases in diff  erent popu-
lations (48–51). These genetic polymorphisms include a tetra-
nucleotide sequence (CATT) that is repeated between fi  ve 
and eight times in the MIF promoter (position −794). An in-
crease in CATT repeat number produces a corresponding 
  increase in MIF promoter activity (48). Individuals with the 
5-CATT (low repeat) MIF allele may be considered low MIF 
expressors, and those bearing non–5-CATT repeats (6-CATT, 
7-CATT, or 8-CATT) may be high MIF expressors.
Plasmodium-infected red cells stimulate MIF secretion by 
cultured macrophages (30). To study the MIF response of 
human cells, we elected to use hemozoin as a stimulant. 
  Hemozoin is a metabolite of Plasmodium hemoglobin degra-
dation that accumulates within the reticuloendothelial system 
of the infected host (52). Hemozoin induces cytokine release 
from monocytes/macrophages (53, 54), and it constitutes a 
Plasmodium-specifi   c, pathogen-associated molecular pattern 
for innate immunity by interaction with the innate receptor 
TLR9 (55). We confi  rmed that hemozoin, which was pre-
pared synthetically from heme chloride (53) and, thus, was 
free of other Plasmodium-produced components, induces MIF 
release from macrophages in a standardized culture system 
(Fig. 8 A). We then added hemozoin to human monocyte 
cultures of predetermined MIF genotype and found that cells 
bearing the low expression 5-CATT (homozygous) allele 
  secreted lower levels of MIF than cells encoding the high 
  expression 6-CATT (homozygous) or 6-CATT/7-CATT 
(heterozygous) alleles (Fig. 8 B). These experimental data, 
which were obtained in vitro, suggest that the host MIF 
  genotype may infl  uence MIF production in response to the 
malarial product hemozoin.
DISCUSSION
Clinical observations have led to the concept that the na-
ture of the host response critically infl  uences the pathologic 
manifestations of malaria infection. Young children and the 
immunologically naive suff  er disproportionately from lethal 
malaria, and it is hypothesized that death results from an 
  exaggerated immunologic response such that the mechanisms 
Figure 6.  Malaria-infected MIF-KO mice show enhanced bone 
marrow erythroid progenitor maturation. (A) CFU-E and BFU-E 
  formation in cultured bone marrow cells harvested from P. chabaudi–
infected or uninfected mice on postinfection day 13. Colonies were 
scored as described in Materials and methods, and the data shown are 
the mean ± SD (error bars) of three mice per group. *, P < 0.01 for 
MIF−/− versus MIF+/+. (B) TNFα, IFNγ, and MIF production in bone 
  marrow lysates obtained from P. chabaudi–infected wild-type (MIF+/+) 
and MIF-KO (MIF−/−) mice. TNFα and IFNγ were measured by ELISA, and 
the data shown are the mean ± SD for fi  ve mice per group. The time-
dependent increase in bone marrow MIF content was assessed by West-
ern blotting of bone marrow samples (240 ng of total protein per lane) 
as described in Materials and methods. The blots show the bone marrow 
analysis of three mice that were studied (I, II, and III). The standard lane 
(fi  rst) shows the immunoblotting intensity of 90 ng of recombinant 
mouse MIF protein.
Figure 7.  Plasma MIF concentrations are elevated in malaria-
  infected individuals. MIF was quantifi  ed by sandwich ELISA in 20 
  sequentially diagnosed subjects with malaria presented to the Macha 
Mission Hospital in Zambia. Control plasmas (n = 20) were obtained con-
temporaneously from uninfected hospital controls. The bottom, middle, 
and top lines of the box mark the 25th, 50th, and 75th percentiles, re-
spectively. The vertical line shows the range of values comprised between 
the 5th and 95th percentiles. The mean plasma MIF concentrations for 
the control and malaria groups were 5.4 and 13.6 ng/ml, respectively 
(P < 0.005 by a two-tailed Student’s t test). Error bars represent SD.1192  MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
initially recruited to fi  ght infection become dysregulated and 
produce life-threatening tissue damage (56, 57). Investigators 
proposed many years ago that the specifi  c pathogenic mani-
festations of malaria, such as severe anemia and cerebral ma-
laria, result from proinfl  ammatory mediator release by host 
cells interacting with malaria parasites or their products (22). 
Others reported evidence of a role for activated leukocytes in 
the erythropoietic changes observed during malaria (18), and 
some studies (19, 27) identifi  ed a host-derived circulating 
mediator that acts to suppress erythropoiesis. Individual cyto-
kines such as TNFα, IL-1, and IFNγ have been examined for 
their eff  ects on hematopoiesis, but their eff  ects have been 
judged to be minor or indirect; for instance, by inducing 
other mediators or by aff  ecting the distribution and availabil-
ity of heme iron (20, 28, 58).
MIF has emerged to be an important regulator of innate 
immunity (59). Its proximate actions are to promote down-
stream cytokine and Toll-like receptor expression (32, 60, 61) 
and to sustain cellular responses in the face of activation-
  induced apoptosis (62). MIF release from macrophages in 
  response to Plasmodium-infected red cells and its prominent 
expression in the plasma, spleen, and bone marrow during 
experimental malaria have suggested that MIF may mediate 
erythropoietic suppression (30). Indeed, MIF shares each of 
the properties that have been reported for the malaria-
induced erythropoiesis inhibitor. MIF levels closely correlate 
with peak parasitemia, and its tissue and bone marrow pro-
duction mimic the expression pattern of the malaria-induced 
erythropoiesis inhibitor (19, 20, 28). MIF’s biophysical prop-
erties also match those that have been reported for the circu-
lating inhibitor (31).
Hematopoietic colony assays confi  rm that MIF, in con-
centrations that circulate in patients with malaria infection, is 
a direct and potent inhibitor of erythroid progenitor devel-
opment. Our fi  nding of synergistic inhibition by MIF to-
gether with low, subinhibitory combinations of TNFα or 
IFNγ is not without precedent because similar synergism has 
been observed in studies of MIF’s impact on proinfl  amma-
tory monocyte/macrophage activation (31, 32). In the pro-
genitor cell systems that were examined, MIF’s action was to 
inhibit cytodiff  erentiation and hemoglobin production.
 These data add to our understanding of the infl  ammatory 
pathogenesis of malarial anemia, but it should be emphasized 
that they do not exclude a role for yet additional mediators in 
infl  uencing erythroid development. Diff  erential TH1 and 
TH2 immunologic responses may infl  uence the pathologic 
course of malaria infection, and IL-10 and IL-12 defi  ciencies 
also may contribute to anemia (15, 24, 26, 63). Whether 
these eff  ects can be attributed to the direct action of these 
  cytokines on erythroid progenitors or to regulatory eff  ects 
on other mediators, including MIF, remains to be examined. 
There also is evidence from other disease models that proin-
fl  ammatory cytokines may inhibit erythropoiesis by repress-
ing the synthesis of erythropoietin (64). Clinical studies of 
malarial anemia, however, suggest that erythropoietin levels 
are appropriately elevated for the degree of anemia (14–16), 
although this fi  nding is not uniform (65, 66). High circulat-
ing erythropoietin levels point to an acquired resistance by 
progenitor cells to erythropoietin stimulation, and this eff  ect 
has been recently verifi  ed in a study of P. chabaudi–infected 
mice (21). Signal transduction through MAP kinases has been 
implicated in the functional eff  ects of erythropoietin (35, 40), 
and our data indicate that signals delivered by MIF antago-
nize the normal pattern of MAP kinase phosphorylation that 
is associated with the erythroid diff  erentiation in a progenitor 
line. The potential involvement of other signaling pathways 
that are relevant for erythroid diff  erentiation remain to be 
examined, but an MIF-induced dysregulation in signaling 
may contribute to the suppression of erythropoiesis that ac-
companies other infl  ammatory disease states as well (58).
The idea that MIF has an intrinsic role in the develop-
ment of malarial anemia was verifi  ed by examining mice ge-
netically defi   cient in MIF. MIF-KO mice infected with 
P. chabaudi showed less anemia and decreased mortality when 
Figure 8.  Hemozoin-induced MIF release from mononuclear cells 
is regulated by low and high expression MIF alleles. (A) Hemozoin 
induces MIF release by cultured mouse macrophages. 2 × 106/ml thiogly-
collate-elicited peritoneal macrophages were cultured with synthetically 
prepared hemozoin for the indicated times, and the conditioned medium 
was harvested for MIF ELISA. Values shown are the mean of triplicate 
determinations. (B) Hemozoin-stimulated human mononuclear cells en-
coding the high expression MIF alleles 6-CATT/6-CATT (6/6) or 6-CATT/7-
CATT (6/7) release more MIF protein than cells encoding the low 
expression MIF allele 5-CATT/5-CATT (5/5). Cells were stimulated with 
42 nM hemozoin for 48 h before sampling supernatants for MIF content. 
Values shown are mean ± SD (error bars) of duplicate analyses. *, P < 
0.002 for 6/6 versus 5/5; *, P < 0.001 for 6/7 versus 5/5; *, P < 0.02 for 
6/7 versus 6/6.JEM VOL. 203, May 15, 2006  1193
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compared with their wild-type infected counterparts. Al-
though it may be argued that the impact of MIF defi  ciency 
on either mortality or anemia in this experimental mouse 
model is not dramatic, it is consistent with MIF’s infl  uence 
on the component of anemia that is attributable to erythroid 
suppression. Indeed, enumeration of bone marrow cultures 
revealed increases in CFU-E and BFU-E of the malaria-
  infected MIF-KO mice when compared with the wild-type 
controls (P < 0.01).
Longitudinal studies in malaria patients to examine the 
relationship between MIF production and hematologic indi-
ces will be important to perform. The levels of plasma MIF 
that we detected in children with malaria are similar to those 
reported previously in patients with bacterial sepsis, although 
patients with septic shock show even higher circulating MIF 
levels (36). Several case control studies have linked high 
  expression human MIF alleles (6-CATT, 7-CATT, and 
8-CATT) or an associated single-nucleotide polymorphism 
with diff  erent infl  ammatory diseases (48–51). It is notewor-
thy that there is considerable population stratifi  cation in the 
distribution of MIF alleles, suggesting that this locus may 
have been subject to diff  erential selective pressure in diff  erent 
regions or ethnic groups (67). We found that malarial hemo-
zoin stimulates MIF protein production from primary human 
mononuclear cells in amounts that refl  ect the low (5-CATT) 
versus the higher (6-CATT and 7-CATT) expression geno-
type of the cells. Our data indicate that the MIF locus may 
regulate the monocyte/macrophage response to this proin-
fl  ammatory malarial product. Hemozoin is poorly degraded 
in vivo, and, once formed in host tissues, it may act as a per-
sistent infl  ammatory focus to sustain the production of MIF 
and other cytokines. Hemozoin deposition within the bone 
marrow (30) also may explain why reticulocytosis and bone 
marrow recovery are often delayed despite the cure of infec-
tion in human malaria (8, 10). Our studies point to the dele-
terious eff  ect of MIF on the clinical expression of malarial 
anemia; however, it is important to consider that in the ap-
propriate context, MIF also may exert important functions 
in the immunologic response to Plasmodium infection.
Whether the human MIF gene infl  uences the clinical ex-
pression of malaria and the development of complications 
such as severe anemia is of interest, and this question can be 
addressed by examining the association between MIF alleles 
and disease manifestations in a malaria-endemic population. 
Such information may facilitate the identifi  cation of individ-
uals who are at high risk for severe malarial anemia or other 
complications so that steps can be taken to prevent or better 
treat their disease.
MATERIALS AND METHODS
Cytokines, antibodies, and reagents. Recombinant mouse or human 
MIF were prepared, and the proteins were purifi  ed essentially free of endo-
toxin (<1 pg endotoxin/μg protein) as described previously (31). The neu-
tralizing anti-MIF mAb (IgG1 isotype) and an isotypic control antibody 
(5D4-11; American Type Culture Collection) were purifi  ed by Mono-Q 
fast protein liquid chromatography. 2.7 × 105 U/μg recombinant mouse 
TNFα and 8.4 × 103 U/μg IFNγ were obtained from R&D Systems. 
  Hemozoin was prepared synthetically from hemin chloride (Sigma-Aldrich) 
under endotoxin-free conditions (53).
Cytokine quantifi  cation. MIF was measured by sandwich ELISA (36) us-
ing human or mouse MIF-specifi  c antibodies developed in our laboratory. 
The MIF content of bone marrow was determined by Western blotting and 
detection with rabbit polyclonal antibody. TNFα and IFNγ levels in sera 
and in supernatants of bone marrow lysates were measured by the Quanti-
kine M TNFα or IFNγ Immunoassay kit (R&D Systems).
Mice and mouse cell cultures. The MIF−/− (MIF-KO) mice (45) were 
bred onto the BALB/c genetic background and studied between 8–10 wk of 
age. The mice were at generation N6. All mouse studies were performed in 
accordance with protocols approved by our Institutional Animal Care and 
Use Committees.
Bone marrow precursors were harvested from the femora and tibia of 
mice in 3 ml of Iscove’s modifi  ed Dulbecco’s medium containing 2% FBS. 
The viability of marrow cells was determined to be >97% by trypan blue 
exclusion staining. Bone marrow lysates were collected by fl  ushing  two 
  femurs and two tibias per mouse with 1 ml of lysis buff  er (150 mM NaCl, 
50 mM Tris, pH 7.5, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, and 
2 mM EDTA) using a 25 G 5/8-gauge needle. The bone marrow plug was 
homogenized, the cellular debris was pelleted, and the lysate supernatant was 
concentrated using a Centricon 10 membrane (Amico). Mouse macrophages 
were prepared from the adherent cultures of thioglycollate-elicited perito-
neal macrophages as described previously (60).
BFU-E and CFU-E progenitor cell assays. The progenitor cell (colony) 
assays were performed according to the standardized methods described pre-
viously (30) and protocols from StemCell Technologies Inc. In brief, washed 
mouse bone marrow cells were plated in sterile 35-mm dishes containing a 
methylcellulose-based medium and growth factors. The total number of 
bone marrow cells plated in duplicate culture dishes were 2 × 105 for CFU-
E and 5 × 105 for BFU-E. MethoCult M3334 was used for the CFU-E and 
BFU-E colony assays. The media for CFU-E and BFU-E was volume ad-
justed by adding one part Isocove’s modifi  ed Dulbecco’s medium to nine 
parts MethoCult M3334 to give fi  nal concentrations of the following com-
ponents: 15% FBS, 1% BSA, 200 mg/ml transferrin, 10 mg/ml insulin, 
1% methylcellulose, 10−4 M 2-mercaptoethanol, 2 mM l-glutamine, and 
3 units/ml erythropoietin. Each assay of diff  erent bone marrow progenitor 
cells was performed independently three to six times.
Erythroid progenitor cell lines. The Friend MEL cell line was cultured 
in Dulbecco’s modifi  ed Eagle’s medium supplemented with 10% FBS. 
  Diff  erentiation was induced with dimethyl sulfoxide diff  erentiation medium 
for 4 d as described previously (34). Hemoglobin synthesis was assessed by 
cytocentrifugation onto glass slides followed by staining with benzidine 
(Worthington) and a hemoglobin kit (Sigma-Aldrich).
The human K562 progenitor cell line (CCL-243; American Type Cul-
ture Collection) was cultured in RPMI/10% FBS supplemented with peni-
cillin and streptomycin. For diff  erentiation, sodium butyrate (Sigma-Aldrich) 
was added to the medium (35). Terminal erythropoietic diff  erentiation was 
measured as described previously (38), and positive cells were enumerated 
after staining with DAF (Sigma-Aldrich). To quantify hemoglobin synthesis, 
the cells were centrifuged and washed in PBS, and the cell pellet was resus-
pended in lysis buff  er (100 mM potassium phosphate, pH 7.8, and 0.2% 
  Triton X-100) before disruption by aspiration through a 21-gauge needle. 
After microcentrifugation, the supernatant was collected, and the hemoglo-
bin concentration was determined using a hemoglobin kit (Sigma-Aldrich). 
Cell viability was assessed by trypan blue dye exclusion and found to be 
equivalent (85–90% viability) between all samples studied.
Western blot analysis. Immunoblotting with antibodies directed against 
phospho–ERK-1/2, total ERK-1/2, phospho–JNK-1/2, total JNK-1/2, 
phospho-p38, and total p38 was performed according to the manufacturer’s 1194  MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
instructions (New England Biolabs, Inc.). The secondary antibody was an 
anti–rabbit IgG conjugated to horseradish peroxidase, and detection was by 
chemiluminescence according to the manufacturer’s instructions (GE 
Healthcare). For quantitation of signal intensity of phospho-specifi  c kinase 
results, Western blots were scanned using a scanner (PowerLook IIII; 
UMAX), and the images were analyzed using UN-SCAN-IT gel Auto-
mated Digitizing system software version 5.1 (Silk Scientifi  c). The ratio be-
tween phosphorylated and total MAP kinase was determined and expressed 
as a fold change for each lane (mean ± SEM for three blots from indepen-
dent cell cultures). The P values were calculated for each of the time course 
comparisons (4, 16, and 96 h) of three diff  erent experiments (two-tailed 
Student’s t test).
Mouse malaria studies. To maintain uniformity of infections, P. chabaudi 
AS was maintained by serial passage in A/J mice, and no more than 10 pas-
sages were allowed before a fresh inoculum was prepared from frozen stocks. 
For simple passages, infection was initiated with a dose of 106–107 parasitized 
erythrocytes. For clinical infections, mice were inoculated intraperitoneally 
with 106 parasitized red blood cells. The course of experimental infection in 
mice was monitored every other day by examining Diff  Quik (Baxter Scien-
tifi  c Products)-stained thin smears from blood. Parasitemias were determined 
by counting a minimum of 200 erythrocytes per blood sample. Hemoglobin 
was determined by using Drabkin’s procedure (Sigma-Aldrich) on 1 μl of 
tail vein blood prepared on every second day, after infection, for 3 wk. Mice 
were observed daily for at least 30 d, and mortality was recorded. At prede-
termined times after infection, fi  ve animals per group were killed by CO2, 
and the blood was collected by cardiac puncture.
Human specimens and cell culture. Blood samples from 20 malaria pa-
tients and 20 uninfected, healthy controls were obtained from the Macha 
Mission Hospital in Choma, Zambia, where P. falciparum is endemic. The 
blood samples were obtained in accordance with research protocols ap-
proved by the institutional review boards of the University of Zambia and 
Yale University. The subjects had acute onset malaria and were diagnosed 
for clinical symptoms (fever, splenomegaly, headache, and malaise) and a 
positive, thick blood fi  lm for parasites. The subjects (12 male and 8 female) 
were between 5–52 mo of age (mean = 25.5 mo) and had a mean hemoglo-
bin of 5.9 g/deciliter. Co-infection by organisms likely to contribute to a 
systemic infl  ammatory response was excluded by clinical evaluation and lab-
oratory testing. Numerical values obtained by MIF-specifi  c sandwich ELISA 
were confi  rmed semiquantitatively by Western blotting.
Human mononuclear cells were prepared from the adherent leukocyte 
fraction of volunteers and genotyped for the (−794) CATT tetranucleotide 
repeat and for a (−173) G/C single-nucleotide polymorphism (48). Two 
homozygous and one heterozygous MIF promoter genotypes were studied: 
5-CATT/5-CATT, 6-CATT/6-CATT, and 6-CATT/7-CATTC. The 
mononuclear cells were cultured in 24-well plates (104 cells/well) and stimu-
lated with 42 nM hemozoin for 48 h. Cells from three individuals were 
studied within each genotyped group, and the results were repeated twice.
Statistics. Data are presented as means ± SD. The signifi  cance level for all 
statistical tests was set at α = 0.05. One-way analysis of variance was per-
formed to determine whether there were diff  erences in the eff  ects of MIF, 
anti-MIF, TNFα, and IFNγ at various doses with respect to colony forma-
tion of bone marrow progenitor cells. Upon fi  nding diff  erences, Bonferroni-
adjusted pairwise (post-hoc) comparisons were performed to determine 
which mediator–dose combination diff  ered from one another. Comparisons 
between cytokine levels, colony formation, and cytokine production be-
tween the MIF+/+ and MIF−/− mice and between normal and malaria-
  infected mice were performed using the two-tailed Student’s t test. For mouse 
survival, the median survival time was compared by the Mann-Whitney test, 
and the overall survival was compared using the χ2 tests (68).
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